Clinical trial
Phase III Study, Multi-center, Open, Randomized, to Assess the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood and Improvement of Quality of Life and Fatigue in Children Under Chemotherapy Treatment.
NCT05704894 is registered in ClinicalTrials.gov with Blau Farmaceutica S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Study, Multi-center, Open, Randomized, to Assess the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood and Improvement of Quality of Life and Fatigue in Children Under Chemotherapy Treatment.
- Lead sponsor
- Blau Farmaceutica S.A.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- May 31, 2023
- Completion date
- November 30, 2025
- Enrollment
- 320 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.